Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/article/10.1007/s00432-017-2574-4/fulltext.html
Reference28 articles.
1. Alba E, Calvo L, Albanell J, De la Haba R, Arcusa lanza A, Chacon JI et al (2012) Chemotherapy and hormonotherpy as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006–03, a multicenter, randomized phase II study. Ann Oncol 23:3069–3074
2. Barnadas A, Gil M, Sanchez-Rovira P et al (2008) Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anticancer Drugs 19:339–347
3. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019–2027
4. Bottini A, Berruti A, Brizzi MP et al (2005) Cytotoxic and antiproliferative activity of the single agent epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single institution phase III trial. Endocr Relat Cancer 12:383–392
5. Buchholz T, Hunt K, Whitman G et al (2003) Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 98:1150–1160
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients;Medical Oncology;2021-11-05
2. Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer;European Journal of Radiology;2019-04
3. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy;Clinical Breast Cancer;2018-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3